HLS Therapeutics Inc. HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS

Rank in Stocks #20386
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Share Price
$2.63
Last synced: 2026-11-18
Market Cap
$81.18M
Change (1 day)
-0.57%
Change (1 year)
-25.86%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for HLS Therapeutics Inc. (HLS)
Operating Margin as of November 2026 TTM: -6.84%
According to HLS Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is -6.84%. At the end of 2025 the company had an operating margin of -7.40%.
Operating Margin history for HLS Therapeutics Inc. from 2000 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -6.84% -7.57%
2025 -7.40% -45.47%
2024 -13.57% -17.31%
2023 -16.41% -24.97%
2022 -21.87% 108.88%
2021 -10.47% -51.39%
2020 -21.54% 151.93%
2019 -8.55% -168.73%
2018 12.44% -59.88%
2017 31.01% -1,419.57%
2016 -2.35% -80.99%
2015 -12.36% -156.49%
2014 21.88% 39.36%
2013 15.70% -16.76%
2012 18.86% -9.76%
2011 20.90% 4.29%
2010 20.04% 254.69%
2009 5.65% -13.48%
2008 6.53% -45.58%
2007 12.00% 341.18%
2006 2.72% -1,395.24%
2005 -0.21% -116.80%
2004 1.25% -80.13%
2003 6.29% -36.08%
2002 9.84% -6.46%
2001 10.52% 304.62%
2000 2.60% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
19.69% -102.88%
DE
19.68% -102.88%
DE
13.26% -101.94%
JP
17.08% -102.50%
CH
10.53% -101.54%
IL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about HLS Therapeutics Inc.'s operating margin

What is HLS Therapeutics Inc.'s operating margin?

HLS Therapeutics Inc.'s operating margin is -6.84%, as of Nov 2026.

What was HLS Therapeutics Inc.'s operating margin in 2025?

In 2025, HLS Therapeutics Inc.'s operating margin was -7.40%, compared with -13.57% in 2024.

How has HLS Therapeutics Inc.'s operating margin changed since 2020?

From 2020 to 2025, HLS Therapeutics Inc.'s operating margin was highest in 2025 (-7.40%) and lowest in 2022 (-21.87%).

How does HLS Therapeutics Inc.'s operating margin compare with similar companies?

HLS Therapeutics Inc.'s operating margin (-6.84%) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with 19.69%.